Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Lisa Bero to Randomized Controlled Trials as Topic

This is a "connection" page, showing publications Lisa Bero has written about Randomized Controlled Trials as Topic.

 
Connection Strength
 
 
 
3.380
 
  1. Bero L. Meta-research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust. PLoS Biol. 2018 04; 16(4):e2005972.
    View in: PubMed
    Score: 0.390
  2. Schroll J, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098.
    View in: PubMed
    Score: 0.318
  3. Bero L. Bias related to funding source in statin trials. BMJ. 2014 Oct 03; 349:g5949.
    View in: PubMed
    Score: 0.306
  4. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014 Apr 29; (4):MR000034.
    View in: PubMed
    Score: 0.297
  5. Walleser S, Hill SR, Bero LA. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. J Clin Epidemiol. 2011 Dec; 64(12):1331-40.
    View in: PubMed
    Score: 0.245
  6. Rasmussen N, Lee K, Bero L. Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials. 2009 Dec 16; 10:116.
    View in: PubMed
    Score: 0.219
  7. Nkansah N, Nguyen T, Iraninezhad H, Bero L. Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes. Public Health Nutr. 2009 Oct; 12(10):1931-7.
    View in: PubMed
    Score: 0.208
  8. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007 Jun; 4(6):e184.
    View in: PubMed
    Score: 0.184
  9. Wilkinson J, Heal C, Antoniou GA, Flemyng E, Avenell A, Barbour V, Bordewijk EM, Brown NJL, Clarke M, Dumville J, Grohmann S, Gurrin LC, Hayden JA, Hunter KE, Lam E, Lasserson T, Li T, Lensen S, Liu J, Lundh A, Meyerowitz-Katz G, Mol BW, O'Connell NE, Parker L, Redman B, Seidler AL, Sheldrick K, Sydenham E, Dahly DL, van Wely M, Bero L, Kirkham JJ. A survey of experts to identify methods to detect problematic studies: stage 1 of the INveStigating ProblEmatic Clinical Trials in Systematic Reviews project. J Clin Epidemiol. 2024 Nov; 175:111512.
    View in: PubMed
    Score: 0.152
  10. Toews I, Anglemyer A, Nyirenda JL, Alsaid D, Balduzzi S, Grummich K, Schwingshackl L, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study. Cochrane Database Syst Rev. 2024 01 04; 1:MR000034.
    View in: PubMed
    Score: 0.145
  11. Turner K, Carboni-Jim?nez A, Benea C, Elder K, Levis B, Boruff J, Roseman M, Bero L, Lexchin J, Turner EH, Benedetti A, Thombs BD. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open. 2020 05 11; 10(5):e035633.
    View in: PubMed
    Score: 0.113
  12. Chartres N, Fabbri A, McDonald S, Turton J, Allman-Farinelli M, McKenzie J, Bero L. Association of industry ties with outcomes of studies examining the effect of wholegrain foods on cardiovascular disease and mortality: systematic review and meta-analysis. BMJ Open. 2019 05 19; 9(5):e022912.
    View in: PubMed
    Score: 0.105
  13. Fabbri A, Chartres N, Scrinis G, Bero LA. Study sponsorship and the nutrition research agenda: analysis of randomized controlled trials included in systematic reviews of nutrition interventions to address obesity. Public Health Nutr. 2017 May; 20(7):1306-1313.
    View in: PubMed
    Score: 0.089
  14. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016 11 23; 11:CD010274.
    View in: PubMed
    Score: 0.089
  15. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014 Sep 15; (9):ED000090.
    View in: PubMed
    Score: 0.076
  16. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013 Feb 28; (2):CD010398.
    View in: PubMed
    Score: 0.068
  17. Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of the Cochrane library. Cochrane Database Syst Rev. 2012 Nov 14; 12:ED000048.
    View in: PubMed
    Score: 0.067
  18. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA. 2011 Mar 09; 305(10):1008-17.
    View in: PubMed
    Score: 0.060
  19. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010 Jul 07; (7):CD000336.
    View in: PubMed
    Score: 0.057
  20. Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009 Jun 08; 4(6):e5826.
    View in: PubMed
    Score: 0.053
  21. Wilkinson J, Heal C, Antoniou GA, Flemyng E, Alfirevic Z, Avenell A, Barbour G, Brown NJL, Carlisle J, Clarke M, Dicker P, Dumville JC, Grey A, Grohmann S, Gurrin L, Hayden JA, Heathers J, Hunter KE, Lasserson T, Lam E, Lensen S, Li T, Li W, Loder E, Lundh A, Meyerowitz-Katz G, Mol BW, O'Connell NE, Parker L, Redman BK, Seidler L, Sheldrick KA, Sydenham E, Torgerson D, van Wely M, Wang R, Bero L, Kirkham JJ. Protocol for the development of a tool (INSPECT-SR) to identify problematic randomised controlled trials in systematic reviews of health interventions. BMJ Open. 2024 03 11; 14(3):e084164.
    View in: PubMed
    Score: 0.037
  22. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. JAMA. 2002 Jun 05; 287(21):2805-8.
    View in: PubMed
    Score: 0.033
  23. Soares-Weiser K, Lasserson T, Jorgensen KJ, Woloshin S, Bero L, Brown MD, Fischhoff B. Policy makers must act on incomplete evidence in responding to COVID-19. Cochrane Database Syst Rev. 2020 11 20; 11:ED000149.
    View in: PubMed
    Score: 0.029
  24. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53.
    View in: PubMed
    Score: 0.019
  25. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009 Nov 12; 361(20):1963-71.
    View in: PubMed
    Score: 0.014
  26. Grimshaw J, McAuley LM, Bero LA, Grilli R, Oxman AD, Ramsay C, Vale L, Zwarenstein M. Systematic reviews of the effectiveness of quality improvement strategies and programmes. Qual Saf Health Care. 2003 Aug; 12(4):298-303.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)